Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix, Illumina Ink Alliance

NEW YORK (GenomeWeb News) – CombiMatrix disclosed in a filing today with the US Securities and Exchange Commission that it has entered into a supply agreement with Illumina.

The filing offers few details of the agreement, and CombiMatrix officials were unavailable for comment by the time this article was published.

The Mukilteo, Wash.-based firm said that it has agreed to sell to Illumina certain CombiMatrix products for use in or sale with Illumina products and applications. The deal is subject to certain minimum purchase order commitments, and Illumina has an option to purchase exclusive rights to use and sell those CombiMatrix products in a designated field, according to the filing.

A few weeks ago, CombiMatrix said that it had hired investment bank Robert W. Baird as a financial and strategic advisor to help the firm review "certain strategies aimed at unlocking shareholder value and creating synergistic relationships."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.